HR 8032 United States House · 119th Congress

FAIC Act

The FAIC Act requires Medicare to pay separately for certain high-cost cancer treatments starting in 2026, rather than bundling them into general outpatient service payments. This change applies to FDA-approved cancer drugs and biologics that do not receive special transitional payments and cost at least $350 per day. The separate payment amount will be based on the drug's average sales price or, if unavailable, its wholesale acquisition cost or mean unit cost. The law includes a budget neutrality provision to ensure total Medicare spending remains unchanged by adjusting other payments as needed.
Bill status in committee 1 of 4 stages cleared
Introduction
Mar 2026
Committee Review
Floor Vote
President
Introduced Mar 20, 2026 Last action Mar 20, 2026
Floor votes

How they voted

No floor votes recorded yet.
Full legislative history

Actions timeline

Total actions
2
Key actions
0
Committee
1
Mar 20, 2026
Committee
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
lower
Mar 20, 2026
Introduced
Introduced in House
lower
1 primary · 6 co-sponsors

Sponsors